8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Apr 27, 2026·SEC
Oncolytics Biotech Inc.(ONCY)Earnings, Financials & Key Ratios
ONCY•NASDAQ
Price updated Jun 19, 2026
AboutOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Show more
- Revenue$0
- EBITDA-$39M-12.7%
- Net Income-$39M-24.4%
- EPS (Diluted)-0.41
- ROE-10245.92%-5319.6%
ONCY Key Insights
Oncolytics Biotech Inc. (ONCY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 18.7% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 25.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ONCY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ONCY Price & Volume
Oncolytics Biotech Inc. (ONCY) stock price & volume — 10-year historical chart
Loading chart...
ONCY Growth Metrics
Oncolytics Biotech Inc. (ONCY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-18.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.92%
Return on Capital
10 Years-150.73%
5 Years-167.33%
3 Years-242.23%
Last Year-507.52%
ONCY Recent Earnings
Oncolytics Biotech Inc. (ONCY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.08-60.0%
$0.05
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.08-33.3%
$0.06
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.10+16.7%
$0.12
Rev
—
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.05+54.5%
$0.11
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.08vs $0.05-60.0% | — |
| Q2 2026 | Mar 30, 2026 | $0.08vs $0.06-33.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.10vs $0.12+16.7% | — |
| Q3 2025 | Aug 8, 2025 | $0.05vs $0.11+54.5% | — |
Based on last 12 quarters of dataView full earnings history →
ONCY Peer Comparison
Oncolytics Biotech Inc. (ONCY) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 CLDX | 2.16B | 32.43 | -8.32 | -78.63% | -345.96% | -50.72% | 0.00 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 VVOS | 2.94M | 0.50 | -0.24 | 16.05% | -128.36% | -23.38% | ||
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 | |
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% |
Compare ONCY vs Peers
Oncolytics Biotech Inc. (ONCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ONCY Income Statement
Oncolytics Biotech Inc. (ONCY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 90.77K | 95.38K | 485.57K | 332.65K | 360.57K | 301.11K | 298.59K | 0 | 0 | 16K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -90.77K▲ 0% | -95.38K▼ 5.1% | -485.57K▼ 409.1% | -332.65K▲ 31.5% | -360.57K▼ 8.4% | -301.11K▲ 16.5% | -298.59K▲ 0.8% | 0▲ 100.0% | 0▲ 0% | -16K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | 44.05% | -5.08% | -409.12% | 31.49% | -8.39% | 16.49% | 0.84% | 100% | - | - |
Operating Expenses | 15.61M | 16.66M | 20.69M | 18.65M | 20.56M | 20.38M | 24.74M | 34.98M | 39.41M | 30.99M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 6.21M | 7.08M | 8.84M | 9M | 10.26M | 8.53M | 11.62M | 13.34M | 21.15M | 15.93M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 9.39M | 9.42M | 11.13M | 9.65M | 10.31M | 11.85M | 13.12M | 21.65M | 18.27M | 14.88M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 9.56M | 0 | 0 | 0 | 0 | 0 | 0 | 187K |
Operating Income | -15.61M▲ 0% | -16.66M▼ 6.8% | -20.69M▼ 24.2% | -18.98M▲ 8.3% | -20.93M▼ 10.2% | -20.68M▲ 1.2% | -25.04M▼ 21.1% | -34.98M▼ 39.7% | -39.41M▼ 12.7% | -31.01M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -2.03% | -6.77% | -24.19% | 8.28% | -10.25% | 1.17% | -21.06% | -39.73% | -12.67% | - |
EBITDA | -15.51M | -16.57M | -20.21M | -18.65M | -20.56M | -20.38M | -24.74M | -34.88M | -39.32M | -30.8M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -2.53% | -6.78% | -21.97% | 7.72% | -10.28% | 0.9% | -21.38% | -41% | -12.72% | -0.17% |
D&A (Non-Cash Add-back) | 90.77K | 95.38K | 485.57K | 332.65K | 360.57K | 301.11K | 298.59K | 102K | 96.05K | 203K |
EBIT | -14.83M | -17.27M | -20.14M | -16.78M | -20.94M | -19.01M | -20.49M | -34.98M | -39.41M | -31.82M |
Net Interest Income | 0 | 0 | 179.28K | 90.36K | 99K | 528K | 1.33M | 1.2M | 529.64K | 307K |
Interest Income | 130.1K | 173.5K | 179.28K | 90.36K | 99K | 528K | 1.33M | 1.2M | 529.64K | 307K |
Interest Expense | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 130.1K | 173.5K | -12.43M | 2.2M | -15.88K | 1.67M | 4.55M | 3.4M | 61.74K | -229K |
Pretax Income | -15.48M▲ 0% | -16.49M▼ 6.6% | -33.12M▼ 100.9% | -16.78M▲ 49.3% | -20.94M▼ 24.8% | -19.01M▲ 9.2% | -20.49M▼ 7.8% | -31.58M▼ 54.1% | -39.35M▼ 24.6% | -31.24M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 141.5K | 548.04K | 0 | 0 | 39.42K | 64.52K | 71.87K | 130K | 108.4K | 79K |
Effective Tax Rate % | -0.91% | -3.32% | 0% | 0% | -0.19% | -0.34% | -0.35% | -0.41% | -0.28% | -0.25% |
Net Income | -15.62M▲ 0% | -17.04M▼ 9.1% | -45.55M▼ 167.4% | -16.78M▲ 63.2% | -20.98M▼ 25.0% | -19.08M▲ 9.1% | -20.56M▼ 7.8% | -31.71M▼ 54.2% | -39.46M▼ 24.4% | -34.96M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -3.15% | -9.1% | -167.37% | 63.17% | -25.05% | 9.08% | -7.79% | -54.22% | -24.44% | -18.31% |
Net Income (Continuing) | -15.62M | -17.04M | -33.12M | -16.78M | -20.98M | -19.08M | -20.56M | -31.71M | -39.46M | -31.32M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.12▲ 0% | -1.06▲ 5.4% | -2.06▼ 94.3% | -0.48▲ 76.7% | -0.49▼ 2.1% | -0.43▲ 12.2% | -0.41▲ 4.7% | -0.41▲ 0.0% | -0.41▲ 0.0% | -0.31▲ 0% |
EPS Growth % | 6.67% | 5.36% | -94.34% | 76.7% | -2.08% | 12.24% | 4.65% | 0% | 0% | 15.92% |
EPS (Basic) | -1.12 | -1.06 | -2.06 | -0.48 | -0.49 | -0.43 | -0.41 | -0.41 | -0.41 | - |
Diluted Shares Outstanding | 13.94M | 16.02M | 22.14M | 40.34M | 53.51M | 58.03M | 67.62M | 76.48M | 95.86M | 112.29M |
Basic Shares Outstanding | 13.94M | 16.02M | 22.14M | 40.34M | 53.51M | 58.03M | 67.62M | 76.48M | 95.86M | 112.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ONCY Balance Sheet
Oncolytics Biotech Inc. (ONCY) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 17.82M | 14.45M | 18.93M | 33.74M | 44.9M | 35.68M | 38.17M | 18.88M | 9.39M | 7.49M |
Cash & Short-Term Investments | 11.84M | 13.7M | 14.15M | 31.22M | 41.26M | 32.14M | 34.91M | 15.94M | 7.14M | 5.49M |
Cash Only | 11.84M | 13.7M | 14.15M | 31.22M | 41.26M | 11.67M | 34.91M | 15.94M | 7.14M | 5.49M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 20.47M | 0 | 0 | 0 | 0 |
Accounts Receivable | 4.8M | 51.65K | 0 | 0 | 866K | 521K | 15K | 68K | 786.23K | 961K |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 2.07M | 89.66K | 0 | 0 | 0 | 980K | 0 | 0 |
Total Non-Current Assets | 333.44K | 412.74K | 727.48K | 609.13K | 976K | 1.65M | 647K | 1.31M | 1.01M | 674K |
Property, Plant & Equipment | 333.44K | 412.74K | 727.48K | 609.13K | 976K | 652K | 647K | 1.31M | 1.01M | 674K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 998K | 0 | 0 | 0 | 0 |
Total Assets | 18.15M▲ 0% | 14.87M▼ 18.1% | 19.66M▲ 32.2% | 34.35M▲ 74.7% | 45.88M▲ 33.6% | 37.33M▼ 18.6% | 38.82M▲ 4.0% | 20.19M▼ 48.0% | 10.4M▼ 48.5% | 8.16M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | 22.98% | -18.1% | 32.24% | 74.72% | 33.58% | -18.63% | 3.98% | -48% | -48.46% | -196.67% |
Total Current Liabilities | 5.23M | 2.81M | 12.87M | 2.71M | 2.69M | 3.94M | 4.24M | 6.69M | 8.37M | 5.42M |
Accounts Payable | 3.51M | 1.83M | 3.17M | 1.81M | 594K | 2.25M | 1.08M | 1.09M | 4.81M | 0 |
Days Payables Outstanding | 14.1K | 6.99K | 2.39K | 1.98K | 601.29 | 2.73K | 1.32K | - | - | 51.53K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 166K |
Deferred Revenue (Current) | 1.55M | 927.4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 178.13K | 988.72K | 9.36M | 655.21K | 408K | 79K | 532K | 1.62M | 3.3M | 5.26M |
Current Ratio | 3.41x | 5.13x | 1.47x | 12.45x | 16.69x | 9.05x | 9.01x | 2.82x | 1.12x | 1.38x |
Quick Ratio | 3.41x | 5.13x | 1.47x | 12.45x | 16.69x | 9.05x | 9.01x | 2.82x | 1.12x | 1.38x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 4.64M | 5.86M | 6.9M | 6.88M | 7.09M | 6.89M | 7.02M | 7.52M | 7.24M | 7.87M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 166.43K | 153.17K | 361K | 157K | 290K | 787K | 507.69K | 1.87M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 5.86M | 6.73M | 6.73M | 0 | 0 | 0 | 0 | 0 | 2.62M |
Total Liabilities | 9.87M | 8.67M | 19.77M | 9.59M | 9.78M | 10.83M | 11.26M | 14.2M | 15.62M | 13.29M |
Total Debt | 0 | 0 | 506.27K | 402.06K | 655K | 373K | 423K | 1.06M | 772.51K | 508K |
Net Debt | -11.84M | -13.7M | -13.64M | -30.82M | -40.61M | -11.29M | -34.49M | -14.88M | -6.37M | -4.99M |
Debt / Equity | - | - | - | 0.02x | 0.02x | 0.01x | 0.02x | 0.18x | - | -0.10x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.16x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 8.28M▲ 0% | 6.2M▼ 25.2% | -107.89K▼ 101.7% | 24.75M▲ 23042.0% | 36.1M▲ 45.8% | 26.5M▼ 26.6% | 27.56M▲ 4.0% | 5.98M▼ 78.3% | -5.21M▼ 187.1% | -5.13M▲ 0% |
Equity Growth % | -22.51% | -25.21% | -101.74% | 23041.96% | 45.84% | -26.59% | 4% | -78.29% | -187.13% | -507.97% |
Book Value per Share | 0.59 | 0.39 | -0.00 | 0.61 | 0.67 | 0.46 | 0.41 | 0.08 | -0.05 | -0.05 |
Total Shareholders' Equity | 8.28M | 6.2M | -107.89K | 24.75M | 36.1M | 26.5M | 27.56M | 5.98M | -5.21M | -5.13M |
Common Stock | 271.71M | 285.19M | 311.08M | 356.82M | 391.35M | 404.04M | 430.91M | 438.19M | 0 | 0 |
Retained Earnings | -294.45M | -311.48M | -344.61M | -367.11M | -393.42M | -418.25M | -446M | -477.71M | -589.32M | -438.74M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 373.73K | 607.5K | 4.08M | 4.02M | 388K | 662K | 544K | 961K | 8.54M | 6.22M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ONCY Cash Flow Statement
Oncolytics Biotech Inc. (ONCY) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -14.89M | -11.92M | -19.91M | -22.07M | -22.43M | -23.36M | -28.45M | -26.97M | -27.6M | -28.56M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -19.34% | 19.95% | -66.99% | -10.86% | -1.66% | -4.11% | -21.81% | 5.21% | -2.34% | -54.22% |
Net Income | -15.62M | -17.04M | -33.12M | -22.51M | -26.3M | -24.84M | -27.75M | -31.71M | -39.46M | -34.96M |
Depreciation & Amortization | 90.77K | 95.38K | 485.57K | 446.19K | 452.06K | 392K | 403K | 424K | 96.05K | 209.31K |
Stock-Based Compensation | 578.7K | 1.42M | 1.47M | 2.56M | 3.83M | 2.38M | 2.07M | 2.72M | 4.26M | 7.85M |
Deferred Taxes | 0 | -374.34K | 12.96M | -2.85M | 408.56K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -124.79K | 75.78K | 94.82K | 68.53K | 91.73K | -1.68M | -4.93M | -1.94M | 5.89M | -2.91M |
Working Capital Changes | 180.85K | 3.9M | -1.8M | 209.78K | -907.99K | 391K | 1.76M | 3.54M | 1.62M | 1.26M |
Change in Receivables | -4.77M | 4.77M | -2.02M | 1.98M | -776.39K | 345K | 506K | -53K | 4.03M | -513.24K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.13M |
Cash from Investing | 1.98M | -107.47K | -10.9K | -29.3K | -285.95K | -20.4M | 20.22M | -239K | -8.23K | -16.3K |
Capital Expenditures | -105.77K | -107.47K | -10.9K | -29.3K | -285.95K | -55K | -8K | -239K | -8.23K | -16.3K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 2.09M | 0 | 0 | 0 | 0 | -20.35K | 0 | 0 | 0 | 0 |
Cash from Financing | 12.81M | 13.3M | 21.02M | 39.77M | 33.02M | 12.21M | 31.99M | 6.64M | 19.37M | 22.74M |
Debt Issued (Net) | 0 | 0 | -447.5K | -461K | -366K | -381K | -407K | -348K | 0 | -203K |
Equity Issued (Net) | 12.47M | 13.17M | 18M | 38.3M | 32.91M | 12.57M | 31.62M | 6.92M | 19.41M | 25.35M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 343.44K | 124.95K | 3.47M | 1.94M | 469.68K | 12K | 781K | 65K | -37.05K | -2.41M |
Net Change in Cash | -198.16K▲ 0% | 1.86M▲ 1040.5% | 448.14K▼ 76.0% | 17.07M▲ 3709.4% | 10.04M▼ 41.2% | -29.6M▼ 394.7% | 23.25M▲ 178.5% | -18.97M▼ 181.6% | -8.06M▲ 57.5% | -6.22M▲ 0% |
Free Cash Flow | -15M▲ 0% | -12.03M▲ 19.8% | -19.92M▼ 65.6% | -22.1M▼ 10.9% | -22.72M▼ 2.8% | -23.41M▼ 3.0% | -28.46M▼ 21.6% | -27.2M▲ 4.4% | -27.6M▼ 1.4% | -28.56M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -19.97% | 19.8% | -65.59% | -10.95% | -2.82% | -3.04% | -21.55% | 4.4% | -1.44% | -9.07% |
FCF per Share | -1.08 | -0.75 | -0.90 | -0.55 | -0.42 | -0.40 | -0.42 | -0.36 | -0.29 | -0.25 |
FCF Conversion (FCF/Net Income) | 0.95x | 0.70x | 0.44x | 1.32x | 1.07x | 1.22x | 1.38x | 0.85x | 0.70x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 136.16K | 15.73K | 5.45K | 12K | 35K | 46K | 120K | 184K | 0 | 0 |
ONCY Key Ratios
Oncolytics Biotech Inc. (ONCY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -164.62% | -235.33% | -1496.6% | -136.16% | -68.96% | -60.95% | -76.06% | -189.05% | -10245.92% | 5132.04% |
Return on Invested Capital (ROIC) | - | - | - | - | - | -289.9% | -453.39% | - | - | 247.37% |
Debt / Equity | - | - | - | 0.02x | 0.02x | 0.01x | 0.02x | 0.18x | - | -0.10x |
FCF Conversion | 0.95x | 0.70x | 0.44x | 1.32x | 1.07x | 1.22x | 1.38x | 0.85x | 0.70x | 0.82x |
Related:ONCY Dividend History·ONCY Revenue History·ONCY Price History·ONCY P/E History·ONCY Financial Ratios·ONCY Institutional Holders
ONCY SEC Filings & Documents
Oncolytics Biotech Inc. (ONCY) SEC filings — annual & quarterly reports (10-K, 10-Q)
ONCY Frequently Asked Questions
Oncolytics Biotech Inc. (ONCY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Oncolytics Biotech Inc. (ONCY) grew revenue by 0.0% over the past year. Growth has been modest.
Oncolytics Biotech Inc. (ONCY) reported a net loss of $35.0M for fiscal year 2025.
Dividend & Returns
Oncolytics Biotech Inc. (ONCY) has a return on equity (ROE) of -10245.9%. Negative ROE indicates the company is unprofitable.
Oncolytics Biotech Inc. (ONCY) had negative free cash flow of $28.6M in fiscal year 2025, likely due to heavy capital investments.